Adaptam’s €3M Funding Targets Cancer’s Immune Evasion
Adaptam Therapeutics has raised €3 million to pioneer cancer immunotherapies targeting immunosuppressive myeloid cells. The Spanish biotech’s approach addresses a key limitation in current cancer treatments. This funding signals continued investor confidence in European immuno-oncology innovation.